Gilead Sciences

16 Stories

New Filing by Rand Paul Raises Securities Experts' Eyebrows

Discloses wife's COVID-related stock buy 16 months late, prompting whispers of insider trading

(Newser) - Rand Paul's headline-making week isn't over yet. First the Republican senator from Kentucky was booted from YouTube for a week for spreading misinformation on face masks. Now Paul, one of the most vocal lawmakers to break with federal health officials on how to handle COVID, has made a...

WHO: Remdesivir Doesn't Aid Survival

Clinical trial involved 11K hospitalized patients

(Newser) - A clinical trial by the World Health Organization has shown that the remdesivir has little material effect on patients' chances of surviving COVID-19. The WHO's report on its Solidarity trial, involving remdesivir and three other possible drug treatments, said none of them "substantially affected mortality" among patients or...

Big Question on Hot COVID Drug: How Much Will It Cost?
$4,500 or $10? Manufacturer
of COVID Drug Has Big Decision
in case you missed it
May 10, 2020 1:50 PM CDT

$4,500 or $10? Manufacturer of COVID Drug Has Big Decision

All eyes on Gilead Sciences, manufacturer of remdesivir

(Newser) - Now that the FDA has approved the drug remdesivir for the treatment of COVID-19, a big question looms: How much will it cost? The drug's manufacturer, Gilead Sciences, is donating its current stock, enough to treat about 140,000 patients, reports Barron's , but its pricing decision after that...

FDA Permits Emergency Use of Drug for COVID-19 Patients

Remdesivir might help shorten recovery time

(Newser) - US regulators on Friday allowed emergency use of an experimental drug that appears to help some coronavirus patients recover faster. It is the first drug shown to help fight COVID-19, which has killed more than 230,000 people worldwide. President Trump announced the news at the White House alongside Food...

Market Jumps on New Study of Remdesivir

Maker Gilead's trial found more patients improved when it was given early

(Newser) - Encouraging news on remdesivir as a potential COVID-19 treatment was followed up with discouraging news . Now, a more optimistic report from the drug's maker—and one that drove a more than 400-point jump at market open despite the release of dour GDP news . Gilead on Wednesday revealed the...

Accidental Post Shows Discouraging Results for Drug

Study on remdesivir was briefly posted on WHO website

(Newser) - An early version of a report on the trial results of a drug touted as a COVID-19 treatment threw cold water on those hopes Thursday. A summary of the clinical trial, conducted in China, was accidentally and briefly posted on a World Health Organization website, STAT reports. It showed remdesivir...

Drug Seems to Be Helping 'Severe' Coronavirus Patients

Gilead's remdesivir shows big promise in Chicago, but official results aren't out

(Newser) - You'll likely be hearing a lot about a drug named remdesivir in the coming days. A report from STAT suggests the drug made by Gilead Sciences is showing big promise in treating "severe" coronavirus patients in Chicago. A big caveat: This is not based on the results of...

Chinese Scientists Seek Patent on US Drug to Fight Virus

They say they are acting to 'protect national interests'

(Newser) - Scientists in the city at the center of China’s virus outbreak have applied to patent a drug made by US company Gilead Science Inc. to treat the disease, possibly fueling the conflict over technology policy that helped trigger Washington’s tariff war with Beijing. The government-run Wuhan Institute of...

A Big Donation Meant to Fight HIV, With 'Mixed' Reaction

Gilead Sciences will donate Truvada, but critics say they should cut price for everyone instead

(Newser) - On Thursday, President Trump tweeted the news: An announcement from Secretary of Health and Human Services Alex Azar that Gilead Sciences, manufacturer of the only approved HIV-preventing drug, would donate enough Truvada to treat 200,000 patients each year through at least 2025, and possibly though 2030. Azar noted the...

Insurers Panic Over $1K-a-Day Wonder Drug

Congress demands to know why Sovaldi is so expensive

(Newser) - The FDA only approved Sovaldi in December, but the hepatitis C treatment is already setting records, with as much as $10 billion in sales expected in the first year alone. And why not? It has few side effects, cures 90% of patients, and, oh yeah, costs $1,000 a day....

FDA OKs 4-in-1 HIV Pill
 FDA OKs 4-in-1 HIV Pill 
Aug 27, 2012 5:29 PM CDT

FDA OKs 4-in-1 HIV Pill

Stribild combines 2 drugs sold as Truvada with 2 new drugs

(Newser) - The FDA today gave the green light to a new anti-HIV pill that combines four medicines to combat the virus that causes AIDS. The agency approved Gilead Sciences' Stribild as a once-a-day treatment to control HIV in adults who have not previously been treated for infection. The pill contains two...

FDA Panel Backs First Drug to Block HIV

Truvada, made by Gilead Sciences, is for healthy people at risk

(Newser) - A panel of federal health advisers has endorsed the first drug shown to prevent HIV infection in healthy people, clearing the way for a potentially landmark approval in the 30-year-old effort against the virus that causes AIDS. In a series of votes, the FDA advisory panel recommended approval of the...

AIDS Drugs Slash Risk of Getting HIV in First Place

Pair of studies show minimum 60% drop in infection rate

(Newser) - The same antiretroviral drugs that treat HIV and AIDS can also be used to cut down the risk of contracting HIV in the first place, two new studies show. The dramatic results are just the latest evidence that AIDS drugs can be effective at prevention as well as treatment. While...

Global Patent Pool Scores 4 New AIDS Drugs

It's a major step to benefit poor nations battling disease

(Newser) - Gilead Sciences announced today that it will license four AIDS and hepatitis B drugs to an international patent pool, allowing cheap, generic versions to be produced for sale in low-income countries. The AIDS drugs, which include tenofovir and emtricitabine, represent a major upgrade on the treatments currently available in those...

After 20 Years, Scientists Crack HIV Puzzle

Enzyme integrase made visible for first time

(Newser) - After 40,000 failed trials and "painstakingly slow progress," scientists have solved a puzzle that stumped AIDS researchers for more than 20 years—and their findings could help develop more effective HIV drugs. The researchers at Harvard and Imperial College London grew a crystal that for the first...

Flu Spooks Street; Dow Off 51
 Flu Spooks Street; Dow Off 51 
MARKETS
Apr 27, 2009 3:18 PM CDT

Flu Spooks Street; Dow Off 51

Firms likely to be hurt by reaction to disease see shares drop

(Newser) - Swine flu worried investors but wasn’t enough to spark a full-scale sell-off today, the Financial Times reports. AMR, parent of American Airlines, Marriott, and Expedia fell as investors bet against firms that may be specifically hurt. Shares of Gilead Sciences, developer of Tamiflu, were up nearly 4%, however. The...

16 Stories
Most Read on Newser